Dimerix Says US FDA Confirms Primary Endpoint Supports Approval of Drug Candidate in Kidney Disease Trial
MT Newswires Live
Dec 24, 2025
Dimerix (ASX:DXB) said the US Food and Drug Administration (FDA) confirmed the proposed primary endpoint of percent reduction in proteinuria compared to placebo, which supports approval of drug candidate DMX-200, in the ACTION3 trial for patients with Focal Segmental Glomerulosclerosis, a type of kidney disease, according to a Wednesday filing with the Australian bourse.
The US FDA has requested further information and documentation, which the company expects to provide shortly, the filing said.
The company expects the blinded analysis for the trial to occur in early 2026, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.